Company intelligence / Profile preview

Kephalios

Aix-en-Provence, Provence-Alpes-Côte d’Azur, Francemedicaldevice-network.com ↗

Ownership: Private
Development stage: Other

Overview

Kephalios developed Kalios™, an adjustable mitral annuloplasty ring designed for minimally invasive correction of mitral regurgitation. The first patient was implanted in 2018. Clinical results are ongoing; the technology allows percutaneous adjustment post-surgery to optimize long-term outcomes and potentially reduce need for repeat open-heart procedures. Recent partnerships with Edwards Lifesciences highlight continued development and commercial interest.

Therapeutic areas: Cardiovascular
Modalities: DeviceMinimally invasive surgical instrument
Industry: Implantable Medical Devices

Partnerships

Edwards Lifesciences

Beyond the preview

Go deeper on Kephalios.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kephalios.

Explore the full profile